Source: News BitesTissue Therapies Ltd has been issued a second core VitroGro patent in the US, “Growth Factor Complexes and Modulation of Cell Migration and Growth.”
Other VitroGro patents have been granted in the US, South Korea, South Africa, Australia and New Zealand.
CEO Dr Steven Mercer said the acceptance of the second core VitroGro patent in the US substantially strengthened the IP position and commercial value of the company. “The patent examination process is progressing well in other jurisdictions and I anticipate that we will be able to announce the granting of further patents over the next 12 months,” Dr Mercer said.
STOCK DASHBOARD: November 25, 2009
Tissue Therapies
Closing Price November 24, 2009: 17.0c
Relative Strength (6 months percentile rank): 13.9
Market capitalisation: $19 million
Turnover volume: 207,569.0
Volume Index (1 is average): 1.5
Turnover value: $35,230
Turnover period: 3 years 40 days
Value of $1,000 invested 1 year ago: $1,753
Source: www.BuySellTips.com